ÃÖõ¿õ ¸íÀÇ

ȯÀÚÀÇ ¸¶À½À» ¸ÕÀú »ý°¢Çϴ ȣÈí±âÁúȯ ±ÇÀ§ÀÚ

ÃÖõ¿õ ¸íÀÇ

  • ¼Ò ¼Ó
    °­µ¿°æÈñ´ëÇб³º´¿ø È£Èí±â³»°ú
  • Àü¹®ºÐ¾ß
    ¸¸¼º±âħ, Æó¾ÏÁø´Ü, ¸¸¼º±âµµÁúȯ

°æÈñ´ëÇб³ Àǰú´ëÇÐÀ» Á¹¾÷ÇÏ°í µ¿ ´ëÇпø ¼®¡¤¹Ú»çÇÐÀ§¸¦ ¹Þ¾Ò´Ù. °æÈñÀÇ·á¿ø ÀüÀÓÀÇ¿Í µ¿¼ö¿øº´¿ø È£Èí±â³»°ú °úÀåÀ» °ÅÃÄ °æÈñ´ëÇб³ Àǰú´ëÇÐ ±³¼ö·Î ÀçÁ÷ ÁßÀÌ´Ù. °­µ¿°æÈñ´ëÇб³º´¿ø È£Èí±â¼¾ÅÍÀå °â È£Èí±â³»°ú °úÀå, ÁßȯÀÚ½Ç ½ÇÀåÀ» ¿ªÀÓÇß´Ù. Àü¹®ºÐ¾ß´Â Æó¾Ï, Æó°áÇÙ, ±â°üÁöõ½Ä, ¸¸¼ºÆó¼â¼ºÆóÁúȯÀ¸·Î, ƯÈ÷ Æó¾Ï°ú Æó Áúȯ¿¡¼­ Àü¹®¼ºÀ» ÀÎÁ¤¹Þ°í ÀÖ´Ù. ´©±¸º¸´Ùµµ ȯÀÚÀÇ ÀÔÀå¿¡¼­ ¸¶À½À» ÀÌÇØÇϰí, ºü¸£°í Á¤È®ÇÑ Áø´Ü°ú °³°³ÀÎÀÇ Æ¯¼º¿¡ ¸ÂÃá ÀûÀýÇÑ Ä¡·á¸¦ Á¦°øÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ´Ù. º´¿øÀ» ã´Â ¸ðµç ȯÀÚ°¡ Áúº´ÀÇ Ä¡·á»Ó ¾Æ´Ï¶ó °ÆÁ¤°ú ½É·Á±îÁö ºü¸£°Ô ÇØ¼ÒÇÒ ¼ö ÀÖµµ·Ï µµ¿òÀ» ÁØ´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • °æÈñ´ë ÀÇ´ë Çлç
  • °æÈñ´ë ÀÇ´ë ¼®»ç
  • °æÈñ´ë ÀÇ´ë ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) °­µ¿°æÈñ´ëÇб³º´¿ø Ä¿¹Â´ÏÄÉÀ̼ǽÇÀå
  • úÞ) °­µ¿°æÈñ´ëÇб³º´¿ø È£Èí±â-¾Ë·¹¸£±â³»°úÀå
  • úÞ) °­µ¿°æÈñ´ëÇб³º´¿ø È£Èí±â¼¾ÅÍ ¼¾ÅÍÀå
  • úÞ) ´ëÇÑ °áÇÙ ¹× È£Èí±âÇÐȸ Á¤º¸ÀÌ»ç
  • °­µ¿°æÈñ´ëÇб³º´¿ø ÀÇ·áÇù·Â½Ç ½ÇÀå (2023 ~ 2024)
  • °­µ¿°æÈñ´ëÇб³º´¿ø ÀÇ·áÇù·Â½Ç ºÎ½ÇÀå (2020 ~ 2023)
  • °­µ¿°æÈñ´ëÇб³º´¿ø ÁßȯÀÚ½Ç ½ÇÀå (2018 ~ 2023)
  • °­µ¿°æÈñ´ëÇб³º´¿ø È£Èí±â³»°ú ±³¼ö 2017
  • ¹Ì±¹ ¹Ì³×¼ÒŸ ¸ÞÀÌ¿äŬ¸®´Ð ¹æ¹®±³¼ö (2013 ~ 2014)
  • °­µ¿°æÈñ´ëÇб³º´¿ø È£Èí±â³»°ú Á¶±³¼ö (2008 ~ 2012)
  • °­µ¿°æÈñ´ëÇб³º´¿ø È£Èí±â³»°ú ÀüÀÓ°­»ç (2006 ~ 2008)
  • µ¿¼ö¿øº´¿ø È£Èí±â³»°ú °úÀå (2004 ~ 2006)
  • °æÈñÀÇ·á¿ø È£Èí±â³»°ú ÀüÀÓÀÇ (2002 ~ 2004)

ÇÐȸȰµ¿

Academic activities
  • ´ëÇѳ»°úÇÐȸ Á¤È¸¿ø
  • ´ëÇÑ °áÇÙ ¹× È£Èí±âÇÐȸ Á¤È¸¿ø
  • ´ëÇÑ ÁßȯÀÚÀÇÇÐȸ Á¤È¸¿ø
  • ³»°ú Àü¹®ÀÇ / È£Èí±â³»°ú ºÐ°úÀü¹®ÀÇ
  • ÁßȯÀÚÀÇÇÐ ¼¼ºÎÀü¹®ÀÇ
È£ÈíÀÌ 10³âÀ» ´õ »ì°ÔÇÑ´Ù
´ëÇ¥¼­Àû

È£ÈíÀÌ 10³âÀ» ´õ »ì°ÔÇÑ´Ù

  • ÀúÀÚ(±Û)ÃÖõ¿õ
  • ÃâÆÇ»ç¸ÞÀ̵帶Àεå
  • ¹ßÇàÀÏ2017.12.20
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 1°Ç
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Clinical significance of normalized airflow obstruction in patients with chronic obstructive pulmonary disease
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Respiratory Medicine
Á¦ ¸ñ Polydeoxyribonucleotide Attenuates Airway Inflammation Through A(2A)R Signaling Pathway in PM10-Exposed Mice
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö INTERNATIONAL NEUROUROLOGY JOURNAL
Á¦ ¸ñ Attenuation effect of polydeoxyribonucleotide on inflammatory cytokines and apoptotic factors induced by particulate matter (PM10) damage in human bronchial cells
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
Á¦ ¸ñ Preoperative plateletcrit is a Prognostic Biomarker for Survival in Patients with Non-Small Cell Lung Cancer
¹ßÇ¥³âµµ 2020 ¹ßÇ¥Áö JOURNAL OF CANCER
Á¦ ¸ñ Epidemiology of Antiphospholipid Syndrome in Korea: a Nationwide Population-based Study
¹ßÇ¥³âµµ 2020 ¹ßÇ¥Áö JOURNAL OF KOREAN MEDICAL SCIENCE
Á¦ ¸ñ Radiomics in Oncology: Method and Clinical Applications
¹ßÇ¥³âµµ 2020 ¹ßÇ¥Áö Journal of Magnetics
Á¦ ¸ñ Combination Therapy With Polydeoxyribonucleotide and Pirfenidone Alleviates Symptoms of Acute Respiratory Distress Syndrome in Human Lung Epithelial A549 Cells
¹ßÇ¥³âµµ 2020 ¹ßÇ¥Áö International Neurourology Journal

¸íÀÇqna ¸íÀÇ QnA

Q °¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä

¸¸¼º±âħÀÇ Áø´Ü°ú Ä¡·á
Æó¾ÏÀÇ Áø´Ü
±Þ¼ºÆó¼Õ»óÀÇ Ä¡·á

Q ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?

ȯÀÚ°¡ ¿øÇÏ´Â ¹Ù¸¦ Á¤È®ÇÏ°Ô ÆÄ¾ÇÇϰí ÃÖ´ëÇÑ ¸ÂÃç Áø·á

Q ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

ÀÚ½ÅÀÇ Áõ»óÀ̳ª Áúº´¿¡ ´ëÇÑ ¼²ºÎ¸¥ ÆÇ´Ü°ú ¹«ºÐº°ÇÏ°Ô ½ñ¾ÆÁ® ³ª¿À´Â ºÎÁ¤È®ÇÑ Á¤º¸¿¡ ÀÇÁ¸ÇÏÁö ¸»°í
´ã´ç Àǻ縦 ÃÖ´ëÇÑ ¹Ï°í µû¸£´Â°Ô »óŸ¦ È£Àü½ÃŰ´Â °¡ÀåÁÁÀº ¹æ¹ýÀÔ´Ï´Ù.

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°­µ¿°æÈñ´ëÇб³º´¿ø

Á¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1577-5800
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

°­µ¿°æÈñ´ëÇб³º´¿øÀº Àǰú, ÇÑÀǰú, Ä¡°ú´ëÇÐÀ» ¸ðµÎ º¸À¯ÇÑ º´¿øÀ¸·Î, 3°³ ´ëÇк´¿øÀÇ ¼öÁØ ³ôÀº ÀÇ·á¼­ºñ½º¸¦ ÇÑ ¹ø¿¡ ¹ÞÀ» ¼ö ÀÖ´Ù. ¿¬¸éÀû 24,000¿© Æò º»°ü Áö»ó 14Ãþ, º°°ü Áö»ó 4ÃþÀÇ 800º´»óÀ» °®Ãè´Ù. ³úÁúȯ¡¤°üÀý¡¤Ã´Ãß µî Áúȯ Áß½ÉÀ¸·Î ƯȭµÈ ÇùÁø ÀÇ·á
¼­ºñ½º¸¦ Á¦°øÇÏ´Â ÀÇ¡¤ÇÑ ÇùÁø¼¾ÅÍ, ȯÀÚ ¼¼°è ÃÖ°í ¼öÁØÀÇ Áø·á½Ã½ºÅÛÀ» °®Ãá Àǰú
´ëÇк´¿ø, ÇÑÀÇÇÐÀ» ¼±µµÇÏ´Â ÇÑ¹æ ºê·£µåÆÄÀ§ 1À§ ÇÑÀǰú´ëÇк´¿ø¿Í Àü¹®¼º°ú ÆíÀǼºÀ» °®Ãá ȯÀÚ¸¸Á· º´¿øÀÎ Ä¡°ú´ëÇк´¿øÀÌ ÃÖ»óÀÇ ÀÇ·á¼­ºñ½º¸¦ Á¦°øÇϰí ÀÖ´Ù.

°­µ¿°æÈñ´ëÇб³º´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã °­µ¿±¸ µ¿³²·Î 892

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä